This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Miroslav Backonja, MD; Brad Beinlich, MD; Douglas Dulli, MD; Henry S. Schutta, MD
Department of Neurology University of Wisconsin Madison, WI 53792

Arch Neurol. 1989;46(7):724.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Intravenously administered dihydroergotamine has been the preferred treatment for protracted, severe migraine attacks (status migrainous) for a number of years.¹ The usual limiting factor in the use of dihydroergotamine is nausea and vomiting. Standard antiemetics, such as phomethazine hydrochloride (Phenergan), hydroxyzine and metoclopramide are usually ineffective. Persistent vomiting adds to the distress, may lead to dehydration, and patients usually decline repeated attempts at treatment with dihydroergotamine.

A combination of haloperidol with lorazepam² is used routinely at the Wisconsin Clinical Cancer Center, Madison, for the management of nausea associated with various types of chemotherapy.

We have found that the intravenous administration of 0.5 to 1.0 mg each of haloperidol and lorazepam 15 minutes prior to the intravenous administration of dihydroergotamine prevents nausea and vomiting.

Report of Cases.

—A 37-year-old woman with a long history of classic migraine headaches and a 1-year history of severe depression was . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?